Prevalence, risk factors and outcome of hyperlactataemia in HIV-infected patients.

摘要: Objective We describe the prevalence, risk factors and outcome of hyperlactataemia (HL) in a cohort 140 HIV-infected patients. Patients methods Patients were enrolled consecutively within 3-month period (July to September 1999) followed until 31 October 2000. One hundred forty patients had venous plasma lactate levels measured. HL was defined at baseline by two consecutive > 2.1 mmol/L (upper limit normal). We compared demographic characteristics, immuno-virological parameters, antiretroviral therapy between with (cases) or without (controls). described clinical features HL. Results Among 129 included analysis, found 11 (8.5%), all whom receiving nucleoside reverse transcriptase inhibitors (NRTIs). Cases more likely than controls receive didanosine stavudine (82% vs. 19%, P= 2.7 × 10−6 82% 48%, 0.03, respectively). Only 4/11 cases (36%) symptoms consistent HL. After median follow-up 15 months, level returned normal three who discontinued NRTIs, but only 2/8 did not (P = 0.06). one case experienced lactic acidosis died during follow-up. Mortality rate similar controls. Conclusion HL is associated NRTI use, particular stavudine, discontinuation NRTIs seems be rapid resolution Lactic remains rare long-term does seem poorer controls.